Identification of a cancer stem cell in human brain tumors
- PMID: 14522905
Identification of a cancer stem cell in human brain tumors
Abstract
Most current research on human brain tumors is focused on the molecular and cellular analysis of the bulk tumor mass. However, there is overwhelming evidence in some malignancies that the tumor clone is heterogeneous with respect to proliferation and differentiation. In human leukemia, the tumor clone is organized as a hierarchy that originates from rare leukemic stem cells that possess extensive proliferative and self-renewal potential, and are responsible for maintaining the tumor clone. We report here the identification and purification of a cancer stem cell from human brain tumors of different phenotypes that possesses a marked capacity for proliferation, self-renewal, and differentiation. The increased self-renewal capacity of the brain tumor stem cell (BTSC) was highest from the most aggressive clinical samples of medulloblastoma compared with low-grade gliomas. The BTSC was exclusively isolated with the cell fraction expressing the neural stem cell surface marker CD133. These CD133+ cells could differentiate in culture into tumor cells that phenotypically resembled the tumor from the patient. The identification of a BTSC provides a powerful tool to investigate the tumorigenic process in the central nervous system and to develop therapies targeted to the BTSC.
Similar articles
-
Cancer stem cells in nervous system tumors.Oncogene. 2004 Sep 20;23(43):7267-73. doi: 10.1038/sj.onc.1207946. Oncogene. 2004. PMID: 15378086 Review.
-
Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res. 2005 Dec 1;65(23):10946-51. doi: 10.1158/0008-5472.CAN-05-2018. Cancer Res. 2005. PMID: 16322242
-
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.Stem Cells. 2009 Aug;27(8):1722-33. doi: 10.1002/stem.98. Stem Cells. 2009. PMID: 19544433
-
Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.BMC Cancer. 2008 Oct 22;8:304. doi: 10.1186/1471-2407-8-304. BMC Cancer. 2008. PMID: 18940013 Free PMC article.
-
Glioblastoma and stem cells.Neoplasma. 2008;55(5):369-74. Neoplasma. 2008. PMID: 18665745 Review.
Cited by
-
Silencing BMI1 eliminates tumor formation of pediatric glioma CD133+ cells not by affecting known targets but by down-regulating a novel set of core genes.Acta Neuropathol Commun. 2014 Dec 20;2:160. doi: 10.1186/s40478-014-0160-4. Acta Neuropathol Commun. 2014. PMID: 25526772 Free PMC article.
-
Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm.Oncol Hematol Rev. 2017;13(1):45-55. doi: 10.17925/ohr.2017.13.01.45. Epub 2017 May 23. Oncol Hematol Rev. 2017. PMID: 33959299 Free PMC article.
-
Biological characteristics of Rh123high stem-like cells in a side population of 786-O renal carcinoma cells.Oncol Lett. 2013 Jun;5(6):1903-1908. doi: 10.3892/ol.2013.1270. Epub 2013 Mar 26. Oncol Lett. 2013. PMID: 23833664 Free PMC article.
-
The modulation of ion channels in cancer chemo-resistance.Front Oncol. 2022 Aug 10;12:945896. doi: 10.3389/fonc.2022.945896. eCollection 2022. Front Oncol. 2022. PMID: 36033489 Free PMC article. Review.
-
Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.PLoS One. 2013 May 29;8(5):e64169. doi: 10.1371/journal.pone.0064169. Print 2013. PLoS One. 2013. PMID: 23734191 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials